Page last updated: 2024-11-04

vorinostat and Leukemia, Prolymphocytic, T-Cell

vorinostat has been researched along with Leukemia, Prolymphocytic, T-Cell in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Leukemia, Prolymphocytic, T-Cell: A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Toutah, K1
Nawar, N1
Timonen, S1
Sorger, H1
Raouf, YS1
Bukhari, S1
von Jan, J1
Ianevski, A1
Gawel, JM1
Olaoye, OO1
Geletu, M1
Abdeldayem, A1
Israelian, J1
Radu, TB1
Sedighi, A1
Bhatti, MN1
Hassan, MM1
Manaswiyoungkul, P1
Shouksmith, AE1
Neubauer, HA1
de Araujo, ED1
Aittokallio, T1
Krämer, OH1
Moriggl, R1
Mustjoki, S1
Herling, M1
Gunning, PT1

Other Studies

1 other study available for vorinostat and Leukemia, Prolymphocytic, T-Cell

ArticleYear
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
    Journal of medicinal chemistry, 2021, 06-24, Volume: 64, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, He

2021